Document is current
Any future updates will be listed below
-
Authors
Maas, Silvana C. E.
Baraibar, Iosune https://orcid.org/0000-0002-3500-9641
Lemler, Lea
Butjosa-Espín, Maria https://orcid.org/0000-0001-5860-3996
Blanco Irazuegui, Odei https://orcid.org/0000-0002-9989-0159
Tabernero, Josep https://orcid.org/0000-0002-2495-8139
Elez, Elena https://orcid.org/0000-0002-4653-6324
Seoane, Jose A. https://orcid.org/0000-0002-3856-9177
- License Information
-
More Information
Article History
Received: 4 June 2024
Accepted: 12 March 2026
First Online: 21 April 2026
Competing interests
: I.B. reports accommodation and travel expenses from Amgen, Merck, Sanofi and Servier; and personal speaker honoraria from AstraZeneca and Amgen. E.E. has received personal honoraria from Agenus, Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cure Teq AG, GlaxoSmithKline, Hoffman La Roche, Janssen, Johnson&Johnson, Lilly, Medscape, Merck Serono, MSD, Nordic Group BV, Novartis, Organon, Pfizer, Pierre Fabre, Repare Therapeutics Inc., RIN Institute Inc., Rottapharm Biotech, Sanofi, Seagen International GmbH, Servier and Takeda. J.T. reports personal financial interest in form of scientific consultancy role for Accent Therapeutics, Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Carina Biotech, Cartography Biosciences, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, Johnson & Johnson/Janssen, Larkspur Biosciences, Lilly, Marengo Therapeutics, Menarini, Merus, MSD, Novartis, One-carbon Therapeutics, Ono Pharma USA, Peptomyc, Pfizer, Pierre Fabre, Quantro Therapeutics, Scandion Oncology, Scorpion Therapeutics, Servier, Sotio Biotech, Syntelios AG, Taiho, Takeda Oncology, Theriva Biologics and Tolremo Therapeutics; and stocks from Alentis Therapeutics, Oniria Therapeutics, 1TRIALSP and Pangaea Oncology. The other authors declare no competing interests.
